However, G-CSF has not shown sufficient efficacy for the prevention and treatment of GSD-associated IBD, and therapeutic options for patients who do not respond to traditional therapies have been limited owing to the adverse effects of glucocorticoids and immunomodulators on this metabolic disorder. This evidence concerns the gene CSF3 and disorder of glycogen metabolism.